Sutton, S. Scott
Magagnoli, Joseph
Cummings, Tammy H. http://orcid.org/0000-0001-7978-7157
Dettling, Theresa
Lovelace, Belinda
Christoph, Mary J.
Hardin, James W.
Funding for this research was provided by:
Alexion Pharmaceuticals (IRB #1573544)
Article History
Accepted: 15 April 2023
First Online: 23 May 2023
Change Date: 12 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11239-023-02841-7
Declarations
:
: Funding for this study was provided by Portola Pharmaceuticals, Inc., now Alexion, AstraZeneca Rare Disease, following acquisition by Alexion. Additionally, SSS declares receiving research grants from Xcenda, Boehringer Ingelheim, United Therapeutics, and Gilead Sciences, unrelated to this work. BL, MJC, and TD are employees of Alexion, AstraZeneca Rare Disease. SSS, THC, and JM receive research support from the National Institutes of Health (NIH) grant R01DA054992 and the South Carolina Center for Rural and Primary Healthcare, unrelated to this work. Alexion provided a formal review of the publication. Authors retain control and final authority of publication content and decisions, including the choice of journal.
: Informed consent was waived for this retrospective non-observational study for the Dorn Research Institute IRB.